Literature DB >> 16569601

Improved survival following induction of GVHD following lipopolysaccharide immunization.

Ali Abdul-Hai1, Lola Weiss, Shimon Slavin, Reuven Or.   

Abstract

OBJECTIVE: Graft-vs-host disease (GVHD) is still the primary limitation to the wider application of allogeneic bone marrow transplantation (BMT). On the one hand, it predisposes transplant recipients to risk of bacterial, fungal, and viral infections, on the other, lipopolysaccharide (LPS), an endotoxin found in the cell walls of gram-negative bacteria, has been shown to play a significant role in the development and severity of GVHD following allogeneic myeloablative BMT. Our study focused on immunization of recipient and donor mice with endotoxin prior to transplantation, in an attempt to reduce mortality caused by gram-negative bacterial infections posttransplantation.
MATERIALS AND METHODS: In one experiment, recipient mice were immunized with LPS prior to BMT, whereas in another experiment, donor mice were immunized prior to BMT. The mice were evaluated for development of GVHD and for survival.
RESULTS: Our results showed that injection of low-dose LPS to mice prior to induction of GVHD with allogeneic spleen cells saved more than 40% of the recipients, whereas all mice in the untreated control group died. The survival of recipients of spleen cells from immunized donors rose to 54% and clinical signs of GVHD were attenuated as compared to control mice inoculated with spleen cells obtained from unimmunized donors.
CONCLUSION: This immunization protocol suggests that immunization of the donor or the recipient against LPS prior to transplantation may be protective against gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16569601     DOI: 10.1016/j.exphem.2006.01.004

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  2 in total

1.  Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells.

Authors:  Hongmei Li; Catherine Matte-Martone; Hung Sheng Tan; Srividhya Venkatesan; Jennifer McNiff; Anthony J Demetris; Dhanpat Jain; Fadi Lakkis; David Rothstein; Warren D Shlomchik
Journal:  J Immunol       Date:  2010-11-22       Impact factor: 5.422

2.  Treatment of intestinal graft-versus-host disease with unrelated donor fecal microbiota transplantation capsules: A case report.

Authors:  Dan Mao; Qi Jiang; Ye Sun; Yubo Mao; Lili Guo; Yanqing Zhang; Muran Man; Guifang Ouyang; Lixia Sheng
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.